Nevi and Breslow thickness in melanoma: sex differences?
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
2
10
2019
medline:
5
11
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
A large body of evidence in the scientific literature suggests that the numbers of common and atypical nevi are strong, independent risk factors for the occurrence of cutaneous malignant melanoma. Furthermore, some studies recently found an association between high nevus counts and an improved melanoma prognosis. The aim of this study was to investigate a possible relationship between the number of common and atypical nevi and melanoma prognostic factors. We carried out a retrospective analysis of patients with a histopathologically confirmed diagnosis of melanoma. These patients were treated at the Dermatology Clinic of the University of Florence from January 2000 to December 2013. The main analysis investigated the association of common and atypical nevi with Breslow thickness and ulceration. The number of nevi was investigated as a continuous variable and a categorical variable considering the median number of common nevi, given the skewness of the distribution of common nevi. We analyzed 818 melanoma patients treated from January 2000 to December 2013. We found a sex and nevi interaction: among women, thick melanomas occur more frequently in patients with a low common nevi count (<10); no association was found in men. This sex and nevi interaction was also found considering the association with very thick melanomas (Breslow > 4 mm). Moreover, the presence of an increasing number of atypical nevi was associated with increased risk of ulceration in both sexes. These data provide new perspectives in the differential sex-related biological behavior of melanoma among females and males.
Identifiants
pubmed: 31574530
doi: 10.1097/CMR.0000000000000579
pii: 00008390-202004000-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-184Références
Titus LJ, Clough-Gorr K, Mackenzie TA, Perry A, Spencer SK, Weiss J, et al. Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol. 2013; 168:571–576
Crocetti E, Carli P. Changes from mid-1980s to late 1990s among clinical and demographic correlates of melanoma thickness. Eur J Dermatol. 2003; 13:72–75
Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009; 27:3–9
Crocetti E, Caldarella A, Chiarugi A, Nardini P, Zappa M. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Res. 2010; 20:422–426
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005; 331:481
Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organization for Research and Treatment of Cancer phase III trials. J Clin Oncol. 2012; 30:2240–2247
Nørgaard C, Glud M, Gniadecki R. Are all melanomas dangerous?. Acta Derm Venereol. 2011; 91:499–503
Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, et al. A large skin cancer screening quality initiative: description and first-year outcomes. JAMA Oncol. 2017; 3:1112–1115
Aldridge RB, Zanotto M, Ballerini L, Fisher RB, Rees JL. Novice identification of melanoma: not quite as straightforward as the ABCDs. Acta Derm Venereol. 2011; 91:125–130
Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol. 2013; 68:568–575
Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician. 2003; 32:706–709
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005; 41:28–44
Green A, MacLennan R, Siskind V. Common acquired naevi and the risk of malignant melanoma. Int J Cancer. 1985; 35:297–300
Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer. 1990; 66:387–395
MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet. 1993; 341:1618–1620
Bataille V, Grulich A, Sasieni P, Swerdlow A, Newton Bishop J, McCarthy W, et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case–control study of melanoma in the UK and Australia. Br J Cancer. 1998; 77:505–510
Geller AC, Mayer JE, Sober AJ, Miller DR, Argenziano G, Johnson TM, et al. Total nevi, atypical nevi, and melanoma thickness: an analysis of 566 patients at 2 US centers. JAMA Dermatol. 2016; 152:413–418
International Agency for Research on Cancer. Epidemiological studies on melanocytic naevi: protocol for identifying and recording naevi IARC Internal Report No 90/002. 1990, Lyon: International Agency for Research on Cancer
Ribero S, Davies JR, Requena C, Carrera C, Glass D, Rull R, et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer. 2015; 137:1691–1698
Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis AE, Tate BJ. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol. 1994; 30:40–48
Rivers JK. Is there more than one road to melanoma?. Lancet. 2004; 363:728–730
Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003; 95:806–812
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95:1878–1890
Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008; 112:1795–1804
Voinea S, Blidaru A, Panaitescu E, Sandru A. Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma. J Med Life. 2016; 9:444–448
Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011; 131:719–726
Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002; 95:1562–1568
Dao H Jr, Kazin RA. Gender differences in skin: a review of the literature. Gend Med. 2007; 4:308–328
Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006; 15:971–980
De Giorgi V, Mavilia C, Massi D, Gozzini A, Aragona P, Tanini A, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol. 2009; 145:30–36
Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004; 11:537–551
De Giorgi V, Gori A, Gandini S, Papi F, Grazzini M, Rossari S, et al. Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol. 2013; 168:513–519
Spyropoulos C, Melachrinou M, Vasilakos P, Tzorakoleftherakis E. Expression of estrogen receptors in melanoma and sentinel lymph nodes; a ‘female’ clinical entity or a possible treatment modality?. Eur J Gynaecol Oncol. 2015; 36:123–130
Udovicic-Gagula D, Ahmovic A, Bilalovic N, Doric M. Expression of Ki-67 and estrogen receptor beta in primary cutaneous melanoma as a potential indicator of regional lymph node positivity. Appl Immunohistochem Mol Morphol. 2019; 27:27–32
Joosse A, Collette S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse/progression- free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013; 31:2337–2346
Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011; 131:719–726
Khosrotehrani K, Dasgupta P, Byrom L, Youlden DR, Baade PD, Green AC. Melanoma survival is superior in females across all tumour stages but is influenced by age. Arch Dermatol Res. 2015; 307:731–740
Nosrati A, Wei ML. Sex disparities in melanoma outcomes: the role of biology. Arch Biochem Biophys. 2014; 563:42–50
Newton-Bishop JA, Chang YM, Iles MM, Taylor JC, Bakker B, Chan M, et al. Melanocytic nevi, nevus genes, and melanoma risk in a large case–control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev. 2010; 19:2043–2054
Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Höiom V, et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet. 2010; 87:6–16
Wachsmuth RC, Gaut RM, Barrett JH, Saunders CL, Randerson-Moor JA, Eldridge A, et al. Heritability and gene–environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol. 2001; 117:348–352